Contact Us

Phone: 1-866-61-EISAI (1-866-61-34724)

Fax: 1-866-57-EISAI (1-866-57-34724)

Monday - Friday 8AM - 8PM ET


Medicare Reimbursement Rate

Centers for Medicare & Medicaid Services (CMS) has updated the reported Medicare reimbursement rate for ALOXI® (palonosetron HCl) injection - J2469 - Effective January 1, 2012.


1st Quarter 2012 ALOXI® Medicare reimbursement in the Physician Office setting is $18.467 per 25 mcg1, and in the Hospital Outpatient setting is $18.12 per 25 mcg.2

These payment rates are in effect from January 1, 2012 through March 31, 2012.1


Medicare payment for most drugs administered in the physician office setting is based on the drug's Average Sales Price (ASP) + 6%.1


Medicare payment for non pass-through, separately payable drugs administered in the hospital outpatient setting is based on the drug's Average Sales Price (ASP) + 4%.2


ASP rates are recalculated and released on a quarterly basis by CMS but can be updated more frequently. Please visit the CMS website below for the most up to date information.


For additional information and assistance with ALOXI®, please contact the Eisai Assistance Program at 1-866-61-EISAI or 1-866-61-34724, Monday through Friday from 8:00 A.M. to 8:00 P.M. (Eastern Time).


Medicare Reimbursement Rate – Physician Office

References

1. Centers for Medicare & Medicaid Services Web Site, Medicare, Medicare Part B Drugs Average Sales Price, 2012 ASP Drug Pricing Files, January 2012 ASP Pricing File – Updated December 9, 2011. Accessed on December 13, 2011 at this address: http://www.cms.gov/McrPartBDrugAvgSalesPrice/01a17_2012ASPFiles.asp#TopOfPage. Rates are subject to change.

2. Centers for Medicare & Medicaid Services Web Site, Medicare, Hospital Outpatient PPS, 2012 January Addendum B, Updated December 28, 2011. Accessed on January 2, 2012 at this address: http://www.cms.gov/HospitalOutpatientPPS/AU/list.asp#TopOfPage. Rates are subject to change.

Indication

ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.


Important Safety Information:


For more information about ALOXI® please see full Prescribing Information.




Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.

Distributed and marketed by Eisai Inc. CORP74AR6 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : December 19, 2011 at 5:45pm ET